



Q & M Dental Group (Singapore) Limited

July 2026

Disclaimer:

This presentation may contain forward-looking statements that involve assumptions, risks and uncertainties. Statements in this presentation that are not historical facts are statements of future expectations with respect to the financial conditions, results of operations and businesses, and related plans and objectives. These forward-looking statements are based on the Company's current intentions, plans, expectations, assumptions and views about future events and are subject to risks, uncertainties and other factors, many of which are outside the Company's control.

Because actual results, performance or events could differ materially from the Company's current intentions, plans, expectations, views and assumptions about the future, such forward-looking statements are not, and should not be construed as a representation as to future performance of the Company. It should be noted that the actual performance of the Company may vary significantly from such statements.

While the Company and its affiliates have taken reasonable care to ensure the accuracy and completeness of the information provided in this presentation, they will not be liable for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind) suffered due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information.

Neither the Company nor any of its affiliates shall be liable for the content of information provided by or quoted from third parties. Examples provided are for illustrative purposes only. The information in this presentation is subject to change without notice.

Any recirculation, transmission or distribution of this presentation or any part thereof by any third party requires the prior written permission of the Company. The Company and its affiliates disclaim all responsibility and liability arising in connection with any unauthorised recirculation, transmission or distribution of this presentation or any part thereof.

THE FIRST PAN ASIA-PACIFIC DENTAL COMPANY

THAILAND



33
CLINICS



MALAYSIA



36
CLINICS



SINGAPORE



114



CLINICS

CHINA

CHINA (AOXIN Q & M)



4 HOSPITALS



7 CLINICS

AUSTRALIA



39
CLINICS



AUSTRALIA

Strategic Acquisitions Strengthening Regional Footprint



Australia



Experteeth Dental Group

Acquired: 100%

Transaction
Value:

AUD 150M
(SGD 134.5M)

Structure:

- AUD 65M (SGD 58.3M) Cash for acquisition
- AUD 30M (SGD 26.9M) Inject as share capital
- AUD 55M (SGD 49.3M) Q & M Consideration Shares

Vendor Alignment:

- 15-Year Service Agreement
- 15 Years Share Moratorium
- Escrow Protection

Profit Guarantee:

- 8-Year Commitment



Thailand



Deezy Q & M Dental Group

Acquired: 51%

Transaction
Value:

THB 994.5M
(SGD 38.4M)

Structure:

- THB 700M (SGD 27M) Cash for acquisition
- THB 294.5M (SGD11.4M) Q & M Consideration Shares

Vendor Alignment:

- 15-Year Service Agreement
- 15 Years Share Moratorium
- Escrow Protection

Profit Guarantee:

- 6-Year Commitment

Proposed 2026 Acquisition Highlights

- Australia — 100% Acquisition
- Thailand — 51% Acquisition
- Singapore — Strategic Expansion
- Central PRC — 100% Acquisition through Aoxin Q & M
- Southern PRC — 100% Acquisition through Aoxin Q & M
- Regional Growth
- Long-Term Vendor Alignment
- Profit Guarantee Protection
- Enhanced Healthcare Ecosystem

About Q & M



Revenue:

\$180.7 million

\$197.2 million

EBITDA

\$38.1 million

\$42.4 million

Listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX-ST") since 2009, Q & M Dental Group (Singapore) Limited (the "Company", together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia. Founder-led and backed by a resilient, cash-generative core, the Group operates the largest network of private dental outlets in Singapore and has established a vertically integrated, increasingly regional platform spanning Singapore, Malaysia, the People's Republic of China ("PRC"), and the wider Asia-Pacific region.

Q&M owns the largest network of registered private dental clinics in Singapore and is listed on SGX with a market capitalization of \$527.9 million SGD as of 9 July 2026.

Q&M boasts the most extensive network of dental clinics in Singapore, holding approximately 10% of marketshare.

Synergy - AI & Patient Management System (IDMS)





Cloud-based system

- Cloud-based system integrated with the Q & M Application
- Conveniently & securely store dental records in patients' mobile phones.


AI Dental Xray Pathology Detection

- Detect Dental Pathologies in 10 Secs
- Act as “second pair of eyes” for Dentist
- Medical device licensed in 7 countries - Singapore, Malaysia, Thailand, Australia, Philippines, Vietnam and Indonesia



Automated Dental Charting / Dental Record

- Automated interactive dental chart creation with a click from AI result
- Comprehensive Dental health record for the patient



Education and Training



Q & M College of Dentistry aims to provide a platform for dentists to upgrade their skills and learn best practices in Dentistry, including performing dental procedures with the latest technologies and materials.



Manpower Efficiency



More than 1000 Dentists

Experienced dentists and specialists



More than 1100 Dental Assistants

Alongside experienced area managers to support dentists



More than 300 Admin Team

To support operations

Procurement Power & Dental Labs



Insurance & Corporate Accounts



Risk Management



Profit Guarantee with Clawback



Escrow Account



Share Pledge



15 years Service Agreement



Good Corporate Governance

FIVE-YEAR POST M&A PERFORMANCE ILLUSTRATION

Growth Through Strategic Acquisition

Illustrative Group performance is base on Actual FY2025 plus five proposed acquisitions across Singapore, Australia, Thailand & China

REVENUE

\$425m

by Year 5

PATMI

\$45.8m

3.3x FY2025

EBITDA

\$120.5m

by Year 5

EPS

4.11c

2.8x FY2025

Disclaimer: The figures shown are for illustration purposes only and do not constitute a forecast, projection or guarantee of future performance.


Revenue Performance Illustration

Based on Profit Guarantee

Group revenue grows from \$197m to \$425m — a 2.2x uplift over the plan

424.9

\$'m Year 5



Segment contribution by year - values in \$'m

GROUP TOTAL

FY25	197.2	\$'m	
Y1	341.1	\$'m	acq. year
Y2	358.6	\$'m	+5.1% YoY
Y3	378.3	\$'m	+5.5% YoY
Y4	399.4	\$'m	+5.6% YoY
Y5	424.9	\$'m	+6.4% YoY

Year 1 more than doubles the base as five acquisitions consolidate; organic growth of 5-6% compounds thereafter.

Disclaimer: The figures shown are for illustration purposes only and do not constitute a forecast, projection or guarantee of future performance.


PATMI Performance Illustration

Base on Profit Guarantee

Profit after tax & MI rises to \$45.8m — 3.3x the FY2025 base

45.8

\$'m Year 5



Segment contribution by year - values in \$'m

GROUP TOTAL

FY25	13.9 \$'m	
Y1	34.7 \$'m	acq. year
Y2	37 \$'m	+6.6% YoY
Y3	39.5 \$'m	+6.8% YoY
Y4	42.3 \$'m	+7.1% YoY
Y5	45.8 \$'m	+8.3% YoY

Excludes other gains / losses. Acquisitions are immediately earnings-accretive, adding ~\$21m of PATMI in Year 1 alone.


Disclaimer: The figures shown are for illustration purposes only and do not constitute a forecast, projection or guarantee of future performance.

Earnings Per Share Performance Illustration

Base on Profit Guarantee

EPS nearly triples to 4.11c despite a larger share base from acquisition funding

4.11c
Year 5



EPS in cents - based on weighted shares in issue

EPS GROWTH

1.47c -> 4.11c

FY2025 actual to Year 5 - +180% (2.8x)

SHARE BASE

947m -> 1,114m

New shares issued to fund acquisitions

Earnings accretion outpaces dilution

PATMI grows 3.3x while shares rise only 1.18x — net EPS uplift for holders.


Disclaimer: The figures shown are for illustration purposes only and do not constitute a forecast, projection or guarantee of future performance.

EBITDA Performance Illustration

Base on Profit Guarantee

EBITDA scales from \$42m to \$120m — a 2.8x increase over five years

120.5
\$'m Year 5



Segment contribution by year - values in \$'m

GROUP TOTAL

FY25	42.4 \$'m	
Y1	90.8 \$'m	acq. year
Y2	97 \$'m	+6.8% YoY
Y3	103.9 \$'m	+7.1% YoY
Y4	111.3 \$'m	+7.1% YoY
Y5	120.5 \$'m	+8.3% YoY

Excludes other gains / losses. Southern PRC and Australia are the largest incremental EBITDA contributors by Year 5.

Disclaimer: The figures shown are for illustration purposes only and do not constitute a forecast, projection or guarantee of future performance.

Australia Acquisition — Five-Year Snapshot

Contribution of the Australia acquisition across all four metrics (consolidated from Year 1)

Metric	FY2025	Y1	Y2	Y3	Y4	Y5	Y1 -> Y5
Revenue (\$'m)	—	42.4	45.4	48.7	52.3	56.2	1.3x
EBITDA (\$'m)	—	15.2	16.5	18.1	19.7	21.4	1.4x
PATMI (\$'m)	—	9.4	10.4	11.4	12.6	13.8	1.5x
EPS contribution (cents)	—	0.87	0.95	1.04	1.14	1.24	1.4x

Largest acquisition

Australia is the biggest single acquisition — \$42.4m revenue and \$9.4m PATMI in Year 1.

Steady compounding

Revenue and profit grow ~7-8% each year, reaching \$56.2m revenue by Year 5.

EPS accretive

Adds 0.87c of EPS in Year 1, rising to 1.24c by Year 5.

Disclaimer: All figures are for illustration purposes only and are not a forecast or projection of actual future results. FY2025 shown as not yet acquired; excludes other gains / losses.

Thailand Acquisition — Five-Year Snapshot

Contribution of the Thailand acquisition across all four metrics (consolidated from Year 1)

Metric	FY2025	Y1	Y2	Y3	Y4	Y5	Y1 -> Y5
Revenue (\$'m)	—	19	23.3	28.4	34.5	44.1	2.3x
EBITDA (\$'m)	—	7.2	8.9	10.8	13.1	16.8	2.3x
PATMI (\$'m)	—	2.5	3	3.7	4.5	5.7	2.3x
EPS contribution (cents)	—	0.23	0.28	0.33	0.40	0.51	2.3x

Fastest-growing

Thailand more than doubles across every metric — revenue grows from \$19.0m to \$44.1m.

Strong profit ramp

PATMI climbs from \$2.5m to \$5.7m and EBITDA from \$7.2m to \$16.8m by Year 5.

Rising EPS share

EPS contribution more than doubles, from 0.23c to 0.51c over the plan.

Disclaimer: All figures are for illustration purposes only and are not a forecast or projection of actual future results. FY2025 shown as not yet acquired; excludes other gains / losses.

Five-Year Snapshot

Group totals across all four metrics — FY2025 base to Year 5

Metric	FY2025	Y1	Y2	Y3	Y4	Y5	FY25 -> Y5
Revenue (\$'m)	197.2	341.1	358.6	378.3	399.4	424.9	2.2x
EBITDA (\$'m)	42.4	90.8	97.0	103.9	111.3	120.5	2.8x
PATMI (\$'m)	13.9	34.7	37.0	39.5	42.3	45.8	3.3x
EPS (cents)	1.47	3.20	3.39	3.60	3.83	4.11	2.8x

Accretive from day one

Acquisitions add ~\$21m PATMI and ~\$48m EBITDA in Year 1.

Durable organic growth

Group metrics compound 5-8% every year after consolidation.

Shareholder value

EPS reaches 4.11c — 2.8x FY2025 — despite the enlarged share base.

Disclaimer: All figures are for illustration purposes only and are not a forecast or projection of actual future results. Based on Company FY2025 plus yearly PG (profit growth); excludes other gains / losses.

Further Information

Details on the proposed acquisitions are set out in the following SGX announcements

1

Entry into Binding Sale and Purchase Agreement in respect of the Proposed Thailand Acquisition

Q & M announcement dated
12 July 2026

2

Entry into Sale and Purchase Agreement in respect of the Experteeth Group

Q & M announcement dated
12 July 2026

3

Entry into a Memorandum of Understanding in relation to a Proposed Acquisition of a Dental Group in Singapore

Q & M announcement dated
4 March 2026

4

Entry into a Memorandum of Understanding in relation to the Proposed Acquisition of a Second Dental Group in China

Aoxin Q & M announcement
dated 20 April 2026

5

Entry into a Memorandum of Understanding in relation to the Proposed Acquisition of a Dental Group in China

Aoxin Q & M announcement
dated 27 March 2026

Thank you